The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates
Authors
Keywords
<sup>68</sup>Ga/<sup>177</sup> Lu-PSMA-targeted theragnostic concept, Prostate cancer, <sup>18</sup>F-NaF-PET, Dosimetry
Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume 44, Issue 5, Pages 788-800
Publisher
Springer Nature
Online
2017-01-12
DOI
10.1007/s00259-016-3609-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluation of Prostate Cancer Bone Metastases with 18F-NaF and 18F-Fluorocholine PET/CT
- (2016) M. Beheshti et al. JOURNAL OF NUCLEAR MEDICINE
- (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted -Particle Radiopharmaceutical Therapy
- (2016) A. P. Kiess et al. JOURNAL OF NUCLEAR MEDICINE
- PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
- (2016) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
- (2016) R. P. Baum et al. JOURNAL OF NUCLEAR MEDICINE
- Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent
- (2016) Kristell L.S. Chatalic et al. Theranostics
- Target Definition in Salvage Radiotherapy for Recurrent Prostate Cancer: The Role of Advanced Molecular Imaging
- (2016) Gaël Amzalag et al. Frontiers in Oncology
- Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
- (2015) S. Gillessen et al. ANNALS OF ONCOLOGY
- Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer
- (2015) Levent Kabasakal et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer
- (2015) Clemens Kratochwil et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer
- (2015) Andreas Delker et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients
- (2015) Florian Sterzing et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?
- (2015) Francesco Ceci et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer
- (2015) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen
- (2015) A. P. Kiess et al. JOURNAL OF NUCLEAR MEDICINE
- The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions
- (2015) A. Afshar-Oromieh et al. JOURNAL OF NUCLEAR MEDICINE
- Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy
- (2015) J. J. Morigi et al. JOURNAL OF NUCLEAR MEDICINE
- 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies
- (2015) M. Weineisen et al. JOURNAL OF NUCLEAR MEDICINE
- 68Ga-PSMA ligand PET versus 18F-NaF PET: evaluation of response to 223Ra therapy in a prostate cancer patient
- (2014) Christian Uprimny et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
- (2014) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
- (2014) Christian M. Zechmann et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer
- (2014) S. Vallabhajosula et al. JOURNAL OF NUCLEAR MEDICINE
- Salivary Gland Function 5 Years After Radioactive Iodine Ablation in Patients with Differentiated Thyroid Cancer: Direct Comparison of Pre- and Postablation Scintigraphies and Their Relation to Xerostomia Symptoms
- (2012) Shin Young Jeong et al. THYROID
- Radiolabelling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system
- (2011) Milos Petrik et al. NUCLEAR MEDICINE COMMUNICATIONS
- Salivary Gland Side Effects Commonly Develop Several Weeks After Initial Radioactive Iodine Ablation
- (2009) R. K. Grewal et al. JOURNAL OF NUCLEAR MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started